85%Confidence
0Views
FDASource
2026-04-02Date
Summary
Cipla's Nilotinib Capsules recall due to stability failures indicates potential quality control issues in manufacturing processes, which could impact patient safety and regulatory standing. This may affect Cipla's reputation and market share in oncology generics, particularly for chronic myeloid leukemia treatment.
Actionable: Monitor Cipla's regulatory compliance updates and consider reviewing investment positions in pharmaceutical companies with recent quality control issues.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now